Immunotherapy drug with chemo before breast cancer surgery
Part of Cancer, Skin clinical trials.
This trial tests a new immunotherapy drug called eftilagimod alpha (efti) added to standard chemotherapy before breast cancer surgery. The goal is to see if it helps shrink tumors more effectively in people with early-stage, hormone-receptor-positive, HER2-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer (stage I to III) that is hormone-receptor-positive and HER2-negative.
- You are planning to receive chemotherapy before surgery to shrink the tumor.
- You are 21 years of age or older.
- You are generally in good health, with normal kidney, liver, and blood cell counts.
- You are willing to use effective birth control during treatment and for 6 months after.
- You do not have other serious health issues like uncontrolled heart disease, active autoimmune disease, or a recent serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This trial tests a new combination of two oral medications—imlunestrant (a hormone therapy) and abemaciclib (a drug that blocks cancer growth)—given before surgery. The goal is to see if these drugs can shrink the tumor, using your tumor's growth rate (Ki67) after two weeks of treatment to guide further therapy.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests a combination of stereotactic body radiation therapy (SBRT), chemotherapy, and an immunotherapy drug called AK104 given before surgery to treat triple-negative breast cancer. It aims to see if this approach can shrink tumors more effectively and help patients avoid a mastectomy.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.